LumaBridge
Private Company
Total funding raised: $5M
Overview
LumaBridge is a specialized oncology CRO founded in 2021, offering end-to-end clinical trial services with a focus on immuno-oncology and innovative cancer therapies. The company differentiates itself through deep scientific expertise, particularly from its founder Dr. George Peoples, and a flexible, partnership-oriented model aimed at small to mid-sized biotechs. Its capabilities span project management, regulatory affairs, clinical operations, and data management, with a stated goal of efficiently translating novel therapies from bench to clinic. A key recent development is its joining with Avance Clinical to expand its global oncology development reach.
Technology Platform
Integrated oncology CRO service model leveraging deep immuno-oncology expertise, doctor-to-doctor site relationships, and specialized consulting for funding pathways (e.g., CPRIT, military contracts).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
LumaBridge competes in the fragmented oncology CRO sector against large, full-service global CROs (e.g., IQVIA, Parexel) and numerous small to mid-sized specialty CROs. Its differentiation is based on deep founder-led scientific expertise in immuno-oncology, a flexible partnership model, and a focus on emerging biotech clients, as opposed to the scale and broad resources of larger competitors.